Recludix Pharma (United States)
A clinical-stage company developing oral precision medicines for inflammatory diseases by targeting SH2 domains.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Recludix is a clinical-stage company with leading, innovative platform approaches to discover and develop novel inhibitors for the toughest protein targets. The company is developing oral precision medicines for inflammatory diseases, focusing on SH2 domain inhibitors. It is conducting a Phase 1 study of REX-8756, an oral STAT6 inhibitor, in partnership with Sanofi.
History
Recludix is a clinical-stage company with leading, innovative platform approaches to discover and develop novel inhibitors for the toughest protein targets. The company has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. Recludix is employing this approach first in the development of SH2 domain inhibitors. The company is conducting a Phase 1 study of REX-8756, an oral inhibitor of STAT6, in a strategic development and commercialization partnership with Sanofi. Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/recludix-pharma-united-states · Editorial policy · How profiles are compiled